Clinical distribution,drug resistance profile and carbapenemases types of 158 carbapenem-resistant Enterobacteriale strains
Objective To investigate the clinical distribution,drug-resistance profile and carbapenemases types of carbapenem-resistant Enterobacteriaceae(CRE).Methods A total of 158 CRE strains from 155 patients were isolated from Taizhou Municipal Hospital from January 2016 to June 2023.The source of its specimens,departmental distribution,and drug resistance status were analyzed.The enzyme types of 158 CRE strains were identified using enhanced carbapenemase inhibitor test.Results The CRE strains were mainly isolated from sputum(51.8％),the specimens were most collected from ICU(46.2％),followed by neurosurgery department(12.0％)and urology department(8.2％).The top three species were Klebsiella pneumoniae(65.8％),Escherichia coli(12.0％),and Klebsiella oxytoca(5.1％).Drug susceptibility test results showed that these strains had a low resistance rate to tigecycline(4.4％),colistin(9.4％),followed by Ceftazidime/Avibactam(22.8％).Among the 158 CRE strains,110(69.6％)produced serine carbapenemase A,33(20.9％)produced metalloenzyme B,and 7(4.4％)produced both of carbapenemase A and metalloenzyme B,8(5.1％)had no carbapenemases production.Conclusion Carbapenem-resistant Enterobacteriales have strong drug resistance,but their sensitivity to polymyxin and tigecycline is high,and carbapenem-resistant Enterobacteriales strains mainly produce serine carbap-enemase.Ceftazidime/avibactam is recommended for clinical use due to its good activity against serine carbapenemase-producing Enterobacteriales,especially for Klebsiella pneumoniae infections.
万方数据
维普
